Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biogen ( (BIIB) ) has issued an update.
On May 14, 2026, Biogen completed its approximately $5.3 billion acquisition of Apellis Pharmaceuticals after a tender offer that expired one minute after 11:59 p.m. Eastern Time on May 13, 2026, with about 82.4% of Apellis shares validly tendered. Remaining shares were acquired via a follow‑on merger, Apellis became a wholly owned Biogen subsidiary, and its stock was delisted from Nasdaq, with Apellis shareholders receiving $41 in cash plus a non‑transferable contingent value right per share.
Biogen, Apellis and Equiniti Trust Company entered a contingent value rights agreement under which holders can receive up to $4 per CVR if specified net sales milestones for SYFOVRE are met between 2027 and 2031, with an estimated maximum payout of about $582 million. To help fund the deal Biogen drew down a new $2 billion unsecured term loan facility signed on May 12, 2026, and the addition of EMPAVELI and SYFOVRE, which generated $689 million of net product revenue in 2025, is expected to bolster Biogen’s revenue trajectory and be accretive to non‑GAAP diluted EPS in 2027, strengthening its long‑term growth profile and nephrology expansion.
The most recent analyst rating on (BIIB) stock is a Buy with a $222.00 price target. To see the full list of analyst forecasts on Biogen stock, see the BIIB Stock Forecast page.
Spark’s Take on BIIB Stock
According to Spark, TipRanks’ AI Analyst, BIIB is a Outperform.
The score is driven primarily by solid financial performance (strong cash flow, improved TTM revenue growth, and manageable leverage) and a generally positive earnings update with continued growth-product momentum and reaffirmed outlook. These are tempered by mixed/neutral technical signals, moderate valuation with no dividend yield provided, and near-term earnings pressure from acquired IPR&D charges and higher investment spending.
To see Spark’s full report on BIIB stock, click here.
More about Biogen
Biogen Inc., listed on Nasdaq as BIIB, is a large biopharmaceutical company that develops and commercializes therapies for serious diseases, with a growing focus on neurology, rare kidney disorders and ophthalmology. Through its acquisition of Apellis Pharmaceuticals, Biogen adds marketed products EMPAVELI and SYFOVRE, expanding its presence in complement-driven diseases and accelerating its entry into nephrology.
Average Trading Volume: 1,109,316
Technical Sentiment Signal: Hold
Current Market Cap: $29.43B
See more insights into BIIB stock on TipRanks’ Stock Analysis page.